Survodutide is a dual GIP and GLP-1 receptor agonist studied for its effects on weight loss and metabolic health. It enhances insulin sensitivity, reduces appetite, and promotes fat loss, with applications in type 2 diabetes and obesity treatment.
Survodutide is a dual GIP and GLP-1 receptor agonist studied for its effects on weight loss and metabolic health. It enhances insulin sensitivity, reduces appetite, and promotes fat loss, with applications in type 2 diabetes and obesity treatment.
This website uses cookies to improve your experience. By clicking “Deny”, you consent to the use of Necessary cookies only. You may also accept selected cookies only.
